Globe News Wire
14 Jun 2026, 18:45 UTC · 14w ago
Verdict
Headline takes no side. We score CRNX +0.90 across four claims — strongly bullish.
+0.90strongly bullish
More positive than 96% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Long-term data (up to two years) from PATHFNDR-1 and PATHFNDR-2 show PALSONIFY maintains lower IGF-1 levels and stable symptoms in acromegaly patients.
More positive than 93% of claims this week
PALSONIFY treatment resulted in stable or reduced pituitary tumor volumes for up to 48 weeks.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 79% of claims this week
Combination therapy of PALSONIFY and cabergoline improves biochemical control for patients who have not yet normalized IGF-1 levels.
More positive than 66% of claims this week
Pooled open-label extension data showed no new safety signals, with only 2.4% of patients discontinuing due to adverse events.
More positive than 53% of claims this week
Which stocks this story touches
More positive than 96% of ticker scores this week
The company announced positive long-term clinical data showing its drug PALSONIFY provides durable and consistent control of acromegaly.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
12h ago
+146.4%
Price agrees with the score
$84.95 vs $34.47 close before publication (Jun 12) · not market-adjusted
CRNX chart →
